{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T13:40:04Z","timestamp":1751118004960,"version":"3.41.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The introduction of meningococcal serogroup C (MenC) conjugate vaccines in the United Kingdom and Australia led to an impressive decline in the incidence of invasive disease. This study examined bactericidal antibody titers over time in the UK and Australian children who received a MenC conjugate vaccine in early childhood to test the hypothesis that ongoing boosting of immunity in the absence of further doses of vaccine in some children may contribute to ongoing protection from disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Serum bactericidal assay using rabbit complement (rSBA) titers at each follow-up visit were compared with all preceding visits to identify any \u22654-fold rise in titers. The proportion of children with a \u22654-fold rise in rSBA titers in paired sera at any visit-to-visit comparison was calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Of 392 children with at least one set of paired sera in the Australian cohort, 72 (18.4%) had a \u22654-fold increase in rSBA titers at least one year after vaccination, including six children (1.5%) who showed evidence of boosting twice. Of 234 children with at least one set of paired sera in the UK cohort, 39 (16.7%) had a \u22654-fold rise in rSBA titers at least one year after vaccination including 2 children (0.9%) with evidence of boosting twice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>A substantial minority of children immunized with MenC conjugate vaccine in early childhood had a rise in bactericidal antibody titers in the years after immunization in the absence of booster vaccination. This occurs most commonly at around 6\u20137 years of age corresponding to school entry and greater social mixing and might indicate exposure to MenC carriage.<\/jats:p><\/jats:sec>","DOI":"10.1097\/inf.0000000000001861","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T19:49:06Z","timestamp":1512848946000},"page":"e66-e71","source":"Crossref","is-referenced-by-count":1,"title":["Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children"],"prefix":"10.1097","volume":"37","author":[{"given":"Al-Mamoon","family":"Badahdah","sequence":"first","affiliation":[{"name":"WHO Collaborating Centre for Mass Gatherings and High Consequence\/High Visibility Events, Flinders University, Adelaide, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameneh","family":"Khatami","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Mass Gatherings and High Consequence\/High Visibility Events, Flinders University, Adelaide, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Tashani","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Mass Gatherings and High Consequence\/High Visibility Events, Flinders University, Adelaide, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harunor","family":"Rashid","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Mass Gatherings and High Consequence\/High Visibility Events, Flinders University, Adelaide, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Booy","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Mass Gatherings and High Consequence\/High Visibility Events, Flinders University, Adelaide, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.286.6.688","article-title":"Risk factors for meningococcal disease in college students.","volume":"286","author":"Bruce","year":"2001","journal-title":"JAMA"},{"key":"R2-20230913","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/bmj.304.6819.116","article-title":"Mortality in meningococcal disease.","volume":"304","author":"Cartwright","year":"1992","journal-title":"BMJ"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/340050","article-title":"Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995\u20132000.","volume":"34","author":"Healy","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1542\/peds.2008-0581","article-title":"Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study.","volume":"123","author":"Borg","year":"2009","journal-title":"Pediatrics"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1017\/S0950268816000704","article-title":"Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.","volume":"144","author":"Lawrence","year":"2016","journal-title":"Epidemiol Infect"},{"key":"R8-20230913","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R9-20230913","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"issue":"suppl 1","key":"R11-20230913","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"R12-20230913","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5694\/j.1326-5377.2007.tb00837.x","article-title":"Australia\u2019s century of meningococcal disease: development and the changing ecology of an accidental pathogen.","volume":"186","author":"Patel","year":"2007","journal-title":"Med J Aust"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/INF.0b013e31820e8638","article-title":"Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.","volume":"30","author":"De Wals","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R14-20230913","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.292.20.2491","article-title":"Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.","volume":"292","author":"De Wals","year":"2004","journal-title":"JAMA"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0264-410X(02)00590-X","article-title":"Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine.","volume":"21","author":"Salleras","year":"2003","journal-title":"Vaccine"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2334-12-35","article-title":"Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.","volume":"12","author":"Kaaijk","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"e12144","DOI":"10.1371\/journal.pone.0012144","article-title":"Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.","volume":"5","author":"de Voer","year":"2010","journal-title":"PLoS One"},{"key":"R18-20230913","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00006454-200102000-00007","article-title":"Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.","volume":"20","author":"Rennels","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/INF.0b013e31816b4561","article-title":"Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.","volume":"27","author":"Tejedor","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/adc.2007.136036","article-title":"A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.","volume":"93","author":"Pace","year":"2008","journal-title":"Arch Dis Child"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/CVI.05354-11","article-title":"Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.","volume":"18","author":"Khatami","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 2","key":"R25-20230913","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales.","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"E503","DOI":"10.33321\/cdi.2016.40.57","article-title":"National Neisseria Network. Australian Meningococcal Surveillance Programme annual report, 2015.","volume":"40","author":"Lahra","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"R28-20230913","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"R29-20230913","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","article-title":"Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.","volume":"197","author":"Maiden","year":"2008","journal-title":"J Infect Dis"},{"issue":"suppl 2","key":"R30-20230913","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales.","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"key":"R31-20230913","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R32-20230913","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1586\/erv.11.159","article-title":"Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.","volume":"10","author":"Safadi","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"R33-20230913","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/INF.0b013e31820013d2","article-title":"Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.","volume":"30","author":"Booy","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R34-20230913","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"R36-20230913","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R37-20230913","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/CVI.00102-07","article-title":"Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.","volume":"14","author":"Trotter","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"R38-20230913","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0b013e3181f728fd","article-title":"Persistence of immunity following a booster dose of Haemophilus influenzae type b-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.","volume":"30","author":"Khatami","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R39-20230913","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/INF.0b013e31828672a7","article-title":"Phase II study of a three-dose primary vaccination course of DTPa-IPV\/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.","volume":"32","author":"Khatami","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R40-20230913","doi-asserted-by":"crossref","first-page":"e101672","DOI":"10.1371\/journal.pone.0101672","article-title":"Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines\u2013exploratory analyses within a randomised controlled trial.","volume":"9","author":"Khatami","year":"2014","journal-title":"PLoS One"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201803000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T13:08:42Z","timestamp":1751116122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201803000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001861","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}